content/01.introduction.md:4:NSCLC
content/01.introduction.md:6:adasdkj
content/01.introduction.md:8:Indeedm
content/01.introduction.md:8:supressive
content/01.introduction.md:10:adenocarcinomas
content/01.introduction.md:10:alveoli
content/01.introduction.md:10:BRAF
content/01.introduction.md:10:EGFR
content/01.introduction.md:10:genomic
content/01.introduction.md:10:histological
content/01.introduction.md:10:histological
content/01.introduction.md:10:KRAS
content/01.introduction.md:10:MAPK
content/01.introduction.md:10:NSCLC
content/01.introduction.md:10:NSCLC
content/01.introduction.md:10:SCLC
content/01.introduction.md:10:subtype
content/01.introduction.md:12:metastaized
content/01.introduction.md:14:ALK
content/01.introduction.md:14:autophagy
content/01.introduction.md:14:BRAF
content/01.introduction.md:14:Carboplatin
content/01.introduction.md:14:chemotherapeutics
content/01.introduction.md:14:Cisplatin
content/01.introduction.md:14:EGFR
content/01.introduction.md:14:immunotherapy
content/01.introduction.md:14:immunotherapy
content/01.introduction.md:14:inhibtion
content/01.introduction.md:14:MEK
content/01.introduction.md:14:Paclitaxel
content/01.introduction.md:14:Pemetrexed
content/01.introduction.md:14:ROS
content/01.introduction.md:14:TRK
content/01.introduction.md:16:ARAF
content/01.introduction.md:16:BRAF
content/01.introduction.md:16:BRAF
content/01.introduction.md:16:BRAF
content/01.introduction.md:16:constitutively
content/01.introduction.md:16:CRAF
content/01.introduction.md:16:effciency
content/01.introduction.md:16:EGF
content/01.introduction.md:16:EGF
content/01.introduction.md:16:glutamic
content/01.introduction.md:16:GTP
content/01.introduction.md:16:GTP
content/01.introduction.md:16:GTP
content/01.introduction.md:16:GTP
content/01.introduction.md:16:independet
content/01.introduction.md:16:kinases
content/01.introduction.md:16:kinases
content/01.introduction.md:16:kinases
content/01.introduction.md:16:Kinases
content/01.introduction.md:16:ligand
content/01.introduction.md:16:ligand
content/01.introduction.md:16:ligands
content/01.introduction.md:16:MAPK
content/01.introduction.md:16:MAPK
content/01.introduction.md:16:MAPK
content/01.introduction.md:16:mitogens
content/01.introduction.md:16:NGF
content/01.introduction.md:16:oncogenic
content/01.introduction.md:16:oncogenic
content/01.introduction.md:16:phosphorylates
content/01.introduction.md:16:phosphorylates
content/01.introduction.md:16:RAS
content/01.introduction.md:16:RAS
content/01.introduction.md:16:RAS
content/01.introduction.md:16:RAS
content/01.introduction.md:16:RAS
content/01.introduction.md:16:RAS
content/01.introduction.md:16:RTKs
content/01.introduction.md:16:RTKs
content/01.introduction.md:16:transcriptional
content/01.introduction.md:16:Tyrosine
content/01.introduction.md:16:valine
content/01.introduction.md:18:autophagy
content/01.introduction.md:18:BRAF
content/01.introduction.md:18:BRAF
content/01.introduction.md:18:BRAF
content/01.introduction.md:18:Dabrafenib
content/01.introduction.md:18:kinases
content/01.introduction.md:18:MAPK
content/01.introduction.md:18:MEK
content/01.introduction.md:18:MEK
content/01.introduction.md:18:pre
content/01.introduction.md:18:Trametinib
content/01.introduction.md:21:proto
content/01.introduction.md:23:carinogene
content/01.introduction.md:23:GEMMs
content/01.introduction.md:23:latencies
content/01.introduction.md:23:MNU
content/01.introduction.md:23:pentrance
content/01.introduction.md:23:ressemble
content/01.introduction.md:25:Cre
content/01.introduction.md:25:Cre
content/01.introduction.md:25:doxycycline
content/01.introduction.md:25:inducible
content/01.introduction.md:25:KRAS
content/01.introduction.md:25:LoxP
content/01.introduction.md:25:LoxP
content/01.introduction.md:25:LoxP
content/01.introduction.md:25:polyadenylation
content/01.introduction.md:25:recombinase
content/01.introduction.md:25:transcriptial
content/01.introduction.md:25:transgenes
content/01.introduction.md:27:BRAF
content/01.introduction.md:27:preclinical
content/01.introduction.md:27:transcriptional
content/01.introduction.md:29:adenocarcinomas
content/01.introduction.md:29:BRAF
content/01.introduction.md:29:EGFR
content/01.introduction.md:29:GEMMs
content/01.introduction.md:29:KRAS
content/01.introduction.md:29:MAPK
content/01.introduction.md:31:BRAF
content/01.introduction.md:31:BRAF
content/01.introduction.md:31:BRAF
content/01.introduction.md:31:BRAF
content/01.introduction.md:31:CAAX
content/01.introduction.md:31:cDNA
content/01.introduction.md:31:Cre
content/01.introduction.md:31:Cre
content/01.introduction.md:31:fluorophore
content/01.introduction.md:31:LoxP
content/01.introduction.md:31:LoxP
content/01.introduction.md:31:onco
content/01.introduction.md:31:oncoprotein
content/01.introduction.md:31:TdTomato
content/01.introduction.md:33:adenomas
content/01.introduction.md:33:BRAF
content/01.introduction.md:33:BRAF
content/01.introduction.md:33:BRAF
content/01.introduction.md:33:BRAF
content/01.introduction.md:33:Hanahan
content/01.introduction.md:33:LUAD
content/01.introduction.md:33:MAPK
content/01.introduction.md:33:oncogenic
content/01.introduction.md:33:overide
content/01.introduction.md:33:pneumocytes
content/01.introduction.md:33:proto
content/01.introduction.md:33:suppresed
content/01.introduction.md:33:Surfactant
content/01.introduction.md:33:WNT
content/01.introduction.md:36:egfr
content/01.introduction.md:36:erk
content/01.introduction.md:36:mek
content/01.introduction.md:36:ras
content/01.introduction.md:38:luad
content/01.introduction.md:38:tumorigenesis
content/01.introduction.md:40:BRAF
content/01.introduction.md:40:gemms
content/01.introduction.md:44:wnt
content/01.introduction.md:48:engagment
content/01.introduction.md:48:evoltionary
content/01.introduction.md:48:supression
content/01.introduction.md:50:antigene
content/01.introduction.md:50:decameric
content/01.introduction.md:50:oligomerization
content/01.introduction.md:50:tetramerization
content/01.introduction.md:50:transactivation
content/01.introduction.md:50:transactivation
content/01.introduction.md:50:transcriptional
content/01.introduction.md:50:transcriptional
content/01.introduction.md:50:transcriptional
content/01.introduction.md:52:Fraumeni
content/01.introduction.md:52:leukemias
content/01.introduction.md:56:phenotypes
content/01.introduction.md:56:stressor
content/01.introduction.md:58:cDNA
content/01.introduction.md:58:ectopic
content/01.introduction.md:58:misclassification
content/01.introduction.md:58:RAS
content/01.introduction.md:60:hemizygosity
content/01.introduction.md:60:hotspot
content/01.introduction.md:60:hotspots
content/01.introduction.md:60:tetramer
content/01.introduction.md:60:transcriptional
content/01.introduction.md:62:chemoresistance
content/01.introduction.md:62:Fraumeni
content/01.introduction.md:62:Fraumeni
content/01.introduction.md:62:GOF
content/01.introduction.md:62:GOF
content/01.introduction.md:62:LOF
content/01.introduction.md:62:LOF
content/01.introduction.md:62:missense
content/01.introduction.md:62:missense
content/01.introduction.md:62:tumorigenic
content/01.introduction.md:64:Catenin
content/01.introduction.md:64:CREB
content/01.introduction.md:64:GOF
content/01.introduction.md:64:KRAS
content/02.tubaseq.md:9:BRAF
content/02.tubaseq.md:9:BRAF
content/02.tubaseq.md:9:BRAF
content/02.tubaseq.md:9:BRAF
content/02.tubaseq.md:9:BRAF
content/02.tubaseq.md:9:colorectal
content/02.tubaseq.md:9:dabrafenib
content/02.tubaseq.md:9:differentially
content/02.tubaseq.md:9:GEMMs
content/02.tubaseq.md:9:Identificaton
content/02.tubaseq.md:9:mealanoma
content/02.tubaseq.md:9:mutationas
content/02.tubaseq.md:9:pre
content/02.tubaseq.md:9:targeed
content/02.tubaseq.md:9:trametinib
content/02.tubaseq.md:11:Genomic
content/02.tubaseq.md:11:histiological
content/02.tubaseq.md:11:tumorigenesis
content/02.tubaseq.md:13:acheive
content/02.tubaseq.md:13:bona
content/02.tubaseq.md:13:fide
content/02.tubaseq.md:13:GEMMs
content/02.tubaseq.md:13:GEMMs
content/02.tubaseq.md:13:histological
content/02.tubaseq.md:13:IHC
content/02.tubaseq.md:13:immunohistochemistry
content/02.tubaseq.md:13:scalable
content/02.tubaseq.md:13:suboptimal
content/02.tubaseq.md:15:barcoded
content/02.tubaseq.md:15:BRAF
content/02.tubaseq.md:15:Cre
content/02.tubaseq.md:15:Cre
content/02.tubaseq.md:15:endoing
content/02.tubaseq.md:15:lentiviral
content/02.tubaseq.md:15:mor
content/02.tubaseq.md:15:rcode
content/02.tubaseq.md:15:recombinase
content/02.tubaseq.md:15:uencing
content/02.tubaseq.md:15:Winslow
content/02.tubaseq.md:19:barcode
content/02.tubaseq.md:19:barcoded
content/02.tubaseq.md:19:barcoded
content/02.tubaseq.md:19:barcoded
content/02.tubaseq.md:19:BRAF
content/02.tubaseq.md:19:BRAF
content/02.tubaseq.md:19:Cre
content/02.tubaseq.md:19:genomic
content/02.tubaseq.md:19:genomic
content/02.tubaseq.md:19:lentiviral
content/02.tubaseq.md:19:lentiviral
content/02.tubaseq.md:19:lentiviruses
content/02.tubaseq.md:19:plasmids
content/02.tubaseq.md:19:preperation
content/02.tubaseq.md:19:recombinase
content/02.tubaseq.md:19:sgRNA
content/02.tubaseq.md:19:titer
content/02.tubaseq.md:19:titer
content/02.tubaseq.md:19:tumorigenesis
content/02.tubaseq.md:21:BRAF
content/02.tubaseq.md:21:BRAF
content/02.tubaseq.md:21:BRAF
content/02.tubaseq.md:21:BRAF
content/02.tubaseq.md:21:catenin
content/02.tubaseq.md:21:catenin
content/02.tubaseq.md:21:histologic
content/02.tubaseq.md:21:tumorigenesis
content/02.tubaseq.md:21:tumorigenesis
content/02.tubaseq.md:21:Wnt
content/02.tubaseq.md:23:BRAF
content/02.tubaseq.md:23:BRAF
content/02.tubaseq.md:23:CRISPR
content/02.tubaseq.md:23:immunohistochemistry
content/02.tubaseq.md:23:immunohistochemistry
content/02.tubaseq.md:23:RNAs
content/02.tubaseq.md:27:adenomas
content/02.tubaseq.md:27:adenomas
content/02.tubaseq.md:27:adenomas
content/02.tubaseq.md:27:adenomas
content/02.tubaseq.md:27:BRAF
content/02.tubaseq.md:27:BRAF
content/02.tubaseq.md:27:BRAF
content/02.tubaseq.md:27:BRAF
content/02.tubaseq.md:27:BRAF
content/02.tubaseq.md:27:BRAF
content/02.tubaseq.md:27:BRAF
content/02.tubaseq.md:27:BRAF
content/02.tubaseq.md:27:BRAF
content/02.tubaseq.md:27:doublings
content/02.tubaseq.md:27:doublings
content/02.tubaseq.md:27:histological
content/02.tubaseq.md:27:Oncogenic
content/02.tubaseq.md:27:stromal
content/02.tubaseq.md:27:tumorigenesis
content/02.tubaseq.md:27:WNT
content/03.p53.md:5:adenocarcinomas
content/03.p53.md:5:ARF
content/03.p53.md:5:BRAF
content/03.p53.md:5:BRAF
content/03.p53.md:5:BRAF
content/03.p53.md:5:dedifferentiation
content/03.p53.md:5:GEMMs
content/03.p53.md:5:GEMMs
content/03.p53.md:5:homologues
content/03.p53.md:5:hotspot
content/03.p53.md:5:hotspot
content/03.p53.md:5:MEK
content/03.p53.md:5:missense
content/03.p53.md:5:transcriptome
content/03.p53.md:5:vitro
content/03.p53.md:5:vivo
content/03.p53.md:9:BRAF
content/03.p53.md:9:BRAF
content/03.p53.md:9:BRAF
content/03.p53.md:9:EGFR
content/03.p53.md:9:EGFR
content/03.p53.md:9:EGFR
content/03.p53.md:9:GEMMs
content/03.p53.md:9:histologically
content/03.p53.md:9:KRAS
content/03.p53.md:9:KRAS
content/03.p53.md:9:KRAS
content/03.p53.md:9:LUAD
content/03.p53.md:9:LUAD
content/03.p53.md:9:LUAD
content/03.p53.md:9:MAPK
content/03.p53.md:9:MAPK
content/03.p53.md:9:mutationally
content/03.p53.md:9:oncoproteins
content/03.p53.md:9:pneumocyte
content/03.p53.md:9:Siegel
content/03.p53.md:9:transformative
content/03.p53.md:11:ARF
content/03.p53.md:11:chemoresistance
content/03.p53.md:11:genomic
content/03.p53.md:11:LUAD
content/03.p53.md:11:MDMX
content/03.p53.md:11:phenotypes
content/03.p53.md:11:proliferative
content/03.p53.md:11:TGF
content/03.p53.md:11:transcriptional
content/03.p53.md:11:transcriptional
content/03.p53.md:11:transcriptional
content/03.p53.md:13:BRAF
content/03.p53.md:13:BRAF
content/03.p53.md:13:dysregulation
content/03.p53.md:13:GEMMs
content/03.p53.md:13:homologues
content/03.p53.md:13:hotspots
content/03.p53.md:13:phenotypic
content/03.p53.md:13:tumorigenesis
content/03.p53.md:15:BRAF
content/03.p53.md:15:BRAF
content/03.p53.md:15:hotspot
content/03.p53.md:15:tumorigenesis
content/03.p53.md:15:tumorigenesis
content/03.p53.md:19:BRAF
content/03.p53.md:19:Differentially
content/03.p53.md:19:Tumorigenesis
content/03.p53.md:21:adenovirus
content/03.p53.md:21:BRAF
content/03.p53.md:21:BRAF
content/03.p53.md:21:Cre
content/03.p53.md:21:Cre
content/03.p53.md:21:Cre
content/03.p53.md:21:Dankort
content/03.p53.md:21:heterozygosity
content/03.p53.md:21:heterozygous
content/03.p53.md:21:LOH
content/03.p53.md:21:pfu
content/03.p53.md:21:pneumocytes
content/03.p53.md:21:recombinase
content/03.p53.md:21:Spc
content/03.p53.md:21:surfactant
content/03.p53.md:21:tumorigenic
content/03.p53.md:23:homozygous
content/03.p53.md:26:Dedifferentiation
content/03.p53.md:28:dedifferentiated
content/03.p53.md:28:dedifferentiation
content/03.p53.md:28:dedifferentiation
content/03.p53.md:28:dedifferentiation
content/03.p53.md:28:flfl
content/03.p53.md:28:IHC
content/03.p53.md:28:LUAD
content/03.p53.md:28:LUADs
content/03.p53.md:28:SPC
content/03.p53.md:28:SPC
content/03.p53.md:28:transcriptional
content/03.p53.md:30:ARF
content/03.p53.md:30:ARF
content/03.p53.md:30:ARF
content/03.p53.md:30:atypia
content/03.p53.md:30:BRAF
content/03.p53.md:30:heterozygous
content/03.p53.md:30:homozygous
content/03.p53.md:30:homozygous
content/03.p53.md:30:homozygous
content/03.p53.md:30:homozygous
content/03.p53.md:30:IHC
content/03.p53.md:30:immunofluorescence
content/03.p53.md:30:Immunohistochemistry
content/03.p53.md:30:immunostaining
content/03.p53.md:30:phospho
content/03.p53.md:30:transcriptional
content/03.p53.md:32:BRAF
content/03.p53.md:32:MEK
content/03.p53.md:34:BRAF
content/03.p53.md:34:BRAF
content/03.p53.md:34:BRAF
content/03.p53.md:34:BRAF
content/03.p53.md:34:BRAFi
content/03.p53.md:34:chemotherapies
content/03.p53.md:34:Cre
content/03.p53.md:34:dabrafenib
content/03.p53.md:34:dabrafenib
content/03.p53.md:34:dabrafenib
content/03.p53.md:34:Dabrafenib
content/03.p53.md:34:flfl
content/03.p53.md:34:homologue
content/03.p53.md:34:hotspot
content/03.p53.md:34:lentivirus
content/03.p53.md:34:MAPK
content/03.p53.md:34:MEK
content/03.p53.md:34:MEKi
content/03.p53.md:34:missense
content/03.p53.md:34:phosphorylated
content/03.p53.md:34:proliferative
content/03.p53.md:34:Spc
content/03.p53.md:34:trametinib
content/03.p53.md:34:trametinib
content/03.p53.md:34:Trametinib
content/03.p53.md:37:BRAF
content/03.p53.md:37:transcriptome
content/03.p53.md:39:dedifferentiation
content/03.p53.md:39:mesenchymal
content/03.p53.md:39:MYC
content/03.p53.md:39:phenotypes
content/03.p53.md:39:transcriptional
content/03.p53.md:39:transcriptional
content/03.p53.md:39:transcriptomic
content/03.p53.md:39:upregulated
content/03.p53.md:42:BRAF
content/03.p53.md:42:BRAF
content/03.p53.md:42:Cre
content/03.p53.md:42:Cre
content/03.p53.md:42:Cre
content/03.p53.md:42:Heterozygous
content/03.p53.md:42:homozygous
content/03.p53.md:42:Hotspot
content/03.p53.md:42:Recombinase
content/03.p53.md:42:tumorigenesis
content/03.p53.md:42:wildtype
content/03.p53.md:44:ARF
content/03.p53.md:44:ARF
content/03.p53.md:44:Colocalization
content/03.p53.md:44:dedifferentiation
content/03.p53.md:44:IHC
content/03.p53.md:44:Missense
content/03.p53.md:44:SPC
content/03.p53.md:47:BRAFi
content/03.p53.md:47:BRAFi
content/03.p53.md:47:BRAFi
content/03.p53.md:47:CytotoxRed
content/03.p53.md:47:dabrafenib
content/03.p53.md:47:dabrafenib
content/03.p53.md:47:dabrafenib
content/03.p53.md:47:dabrafenib
content/03.p53.md:47:Ectopic
content/03.p53.md:47:GEMMs
content/03.p53.md:47:Immunoblotting
content/03.p53.md:47:MEKi
content/03.p53.md:47:MEKi
content/03.p53.md:47:phospho
content/03.p53.md:47:timecourse
content/03.p53.md:47:trametinib
content/03.p53.md:47:trametinib
content/03.p53.md:47:trametinib
content/03.p53.md:47:trametinib
content/03.p53.md:47:vitro
content/03.p53.md:47:vitro
content/03.p53.md:50:differentially
content/03.p53.md:50:GSEA
content/03.p53.md:50:transcriptome
content/03.p53.md:50:Upregulated
content/03.p53.md:52:differentially
content/03.p53.md:52:GSEA
content/03.p53.md:52:transcriptome
content/03.p53.md:52:Upregulated
content/03.p53.md:78:adenocarcinomas
content/03.p53.md:78:BRAF
content/03.p53.md:78:Cre
content/03.p53.md:78:Cre
content/03.p53.md:78:dedifferentiation
content/03.p53.md:78:hotspot
content/03.p53.md:78:leukemias
content/03.p53.md:78:missense
content/03.p53.md:78:missense
content/03.p53.md:78:wildtype
content/03.p53.md:78:wildtype
content/03.p53.md:78:wildtype
content/03.p53.md:80:BRAF
content/03.p53.md:80:BRAF
content/03.p53.md:80:dabrafenib
content/03.p53.md:80:heterozygosity
content/03.p53.md:80:missense
content/03.p53.md:80:trametinib
content/03.p53.md:80:tumorigenesis
content/03.p53.md:80:wildtype
content/03.p53.md:80:wildtype
content/03.p53.md:84:adenocarcinomas
content/03.p53.md:84:ARF
content/03.p53.md:84:ARF
content/03.p53.md:84:ARF
content/03.p53.md:84:ARF
content/03.p53.md:84:ARF
content/03.p53.md:84:ARF
content/03.p53.md:84:BRAF
content/03.p53.md:84:BRAF
content/03.p53.md:84:GOF
content/03.p53.md:84:Hyperactivation
content/03.p53.md:84:MAPK
content/03.p53.md:84:MAPK
content/03.p53.md:84:oncogenic
content/03.p53.md:84:PDAC
content/03.p53.md:84:phospho
content/03.p53.md:86:GOF
content/03.p53.md:86:oligomerization
content/03.p53.md:86:transactivation
content/03.p53.md:86:transcriptional
content/03.p53.md:86:transcriptomes
content/03.p53.md:88:BRAF
content/03.p53.md:88:BRAF
content/03.p53.md:88:BRAF
content/03.p53.md:88:chemotherapies
content/03.p53.md:88:GOF
content/03.p53.md:88:Imatinib
content/03.p53.md:88:immunoblotting
content/03.p53.md:88:ligands
content/03.p53.md:88:LSL
content/03.p53.md:88:MEK
content/03.p53.md:88:PDGF
content/03.p53.md:88:PDGFR
content/03.p53.md:88:PDGFR
content/03.p53.md:88:phenotypes
content/03.p53.md:88:transcriptional
content/03.p53.md:90:dabrafenib
content/03.p53.md:90:dedifferentiation
content/03.p53.md:90:pre
content/03.p53.md:90:proliferative
content/03.p53.md:90:trametinib
content/03.p53.md:90:transcriptomes
content/03.p53.md:90:tumorigenic
content/05.futuredirections.md:5:prespectives
